GCM
ARQT icon

Graham Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Graham Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-35,278
Closed -$665K – 1220
2025
Q3 		$665K Sell
35,278
-36,342
-51% -$573K 0.02% 514
2025
Q2 		$1M Buy
71,620
+34,003
+90% +$477K 0.03% 579
2025
Q1 		$588K Buy
37,617
+10,780
+40% +$152K 0.02% 739
2024
Q4 		$374K Buy
26,837
+4,551
+20% +$49.9K 0.01% 842
2024
Q3 		$207K Sell
22,286
-43,879
-66% -$433K 0.01% 900
2024
Q2 		$615K Buy
66,165
+52,699
+391% +$477K 0.02% 521
2024
Q1 		$133K Sell
13,466
-48,951
-78% -$365K ﹤0.01% 946
2023
Q4 		$202K Buy
+62,417
New +$170K 0.01% 841

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return